Glycerol phenylbutyrate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Glycerol phenylbutyrate
Glycerol phenylbutyrate skeletal.svg
Clinical data
Trade namesRavicti
License data
  • US: C (Risk not ruled out)
Routes of
ATC code
Legal status
Legal status
CAS Number
PubChem CID
ECHA InfoCard100.228.552 Edit this at Wikidata
Chemical and physical data
Molar mass530.651 g/mol
3D model (JSmol)

Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[1] It is an FDA-approved prescription drug in the US.[2] It is approved for anyone over 2 months of age. It was developed by Hyperion Theraputics based on the existing drug Buphenyl, and received approval on February 1, 2013.[3] Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[4] In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.


  1. ^ "Archived copy". Archived from the original on 2013-03-07. Retrieved 2013-04-01.CS1 maint: Archived copy as title (link)
  2. ^ Drugs@FDA: FDA Approved Drug Products. [accessed 2018 Feb 18].
  3. ^ Herder M. Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada. Journal of Law and the Biosciences. 2016 [accessed 2018 Feb 18];3(1):158-166. DOI: 10.1093/jlb/lsv060 URL:
  4. ^ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". GEN.

External links[edit]